Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death
worldwide. In the past decade, there have been improvements in non-drug therapies and …

Evidence-based management of patients with hepatocellular carcinoma (HCC) is key to
their optimal care. For individuals at risk for HCC, surveillance usually involves …

Purpose Selective internal radiation therapy or radioembolization (RE) shows efficacy in
unresectable hepatocellular carcinoma (HCC) limited to the liver. This study compared the …

Objective Liver cancer is one of the most common cancers and major cause of cancer
deaths in China, which accounts for over 50% of new cases and deaths worldwide. The …

Chemokines, which are basic proteins that exert their effects via G protein-coupled receptors
and a subset of the cytokine family, are mediators deeply involved in leukocyte migration …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the second
leading cause of cancer-related mortality worldwide. This review is an updated version that …

Hepatocellular carcinoma (HCC) is the predominant primary liver cancer in many countries
and is the third most common cause of cancer-related death in the Asia-Pacific region. The …

Liver cancer ranks the sixth in cancer incidence and the second in tumor related mortality
worldwide, with over half of the new cases and deaths occur in China. Because of difficulties …

Primary liver cancer, mostly hepatocellular carcinoma, remains a difficult-to-treat cancer.
Incidence of liver cancer varies geographically and parallels with the geographic prevalence …

BACKGROUND & AIMS: The Sorafenib Hepatocellular Carcinoma (HCC) Assessment
Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival …